Characteristics of the patients
| Case no. . | Age/sex . | Diagnosis . | HLA typing . | Conditioning regimen29 30 . | Cell source . | Reinfused Cells . | Acute GVHD, grade . | Days to WBC, 1 000/μL . | Days to PLT, 50 000/μL . | Hematopoietic chimerism, % donor cells . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T-cell– depleted BM, × 106/kg . | CD34+ BM cells, × 106/kg . | CD34+ PB cells, × 106/kg . | ||||||||||
| 1 | 44/M | AML | matched | TBI/CTX/TT/ATG | BM + PB | 24 | 0.69 | 6.7 | 0 | 12 | 16 | ND |
| 2 | 38/M | CML | matched | TBI/CTX/TT/ATG | BM + PB | 55 | 1.05 | 5.4 | 0 | 10 | 15 | 100 |
| 3 | 31/M | AML | mismatched | TBI/CTX/TT/ATG | BM | 27 | ND | — | 0 | 28 | 40 | ND |
| 4 | 59/M | AML | matched | TBI/CTX/TT/ATG | BM + PB | 14 | 0.26 | 2.2 | 0 | 12 | 18 | 100 |
| 5 | 54/M | CML | matched | TBI/CTX/TT/ATG | BM | 23 | ND | — | 0 | 17 | 31 | 100 |
| 6 | 45/M | ALL | mismatched | TBI/CTX/TT/ATG | BM + PB | 11 | 0.54 | 4.9 | 0 | 14 | 28 | 100 |
| 7 | 26/M | RAEB-T | mismatched | TBI/FLU/TT/ATG | BM + PB | 13 | 0.26 | 6.9 | 0 | 11 | 48 | 100 |
| 8 | 45/M | CML | matched | TBI/CTX/TT/ATG | BM | 59 | ND | — | 0 | 52 | 72 | 100 |
| 9 | 50/M | CML | matched | TBI/CTX/TT/ATG | BM | 20 | 0.64 | — | 0 | 10 | 38 | 100 |
| 10 | 36/F | AML | matched | TBI/CTX/TT/ATG | BM + PB | 51 | 1.17 | 2.9 | 0 | 14 | 33 | 100 |
| 11 | 25/M | AML | mismatched | TBI/FLU/TT/ATG | PB | — | — | 7.7 | 0 | 12 | 17 | 100 |
| 12 | 51/M | CML | matched | TBI/CTX/TT/ATG | BM | 45 | ND | — | 0 | 22 | 26 | 100 |
| 13 | 47/M | AML | mismatched | TBI/FLU/TT/ATG | BM + PB | 12 | 0.19 | 4.6 | 0 | 11 | 27 | 100 |
| 14 | 29/F | CML | mismatched | TBI/CTX/TT/ATG | BM + PB | 12 | 0.48 | 9 | 0 | 13 | 16 | 100 |
| Case no. . | Age/sex . | Diagnosis . | HLA typing . | Conditioning regimen29 30 . | Cell source . | Reinfused Cells . | Acute GVHD, grade . | Days to WBC, 1 000/μL . | Days to PLT, 50 000/μL . | Hematopoietic chimerism, % donor cells . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T-cell– depleted BM, × 106/kg . | CD34+ BM cells, × 106/kg . | CD34+ PB cells, × 106/kg . | ||||||||||
| 1 | 44/M | AML | matched | TBI/CTX/TT/ATG | BM + PB | 24 | 0.69 | 6.7 | 0 | 12 | 16 | ND |
| 2 | 38/M | CML | matched | TBI/CTX/TT/ATG | BM + PB | 55 | 1.05 | 5.4 | 0 | 10 | 15 | 100 |
| 3 | 31/M | AML | mismatched | TBI/CTX/TT/ATG | BM | 27 | ND | — | 0 | 28 | 40 | ND |
| 4 | 59/M | AML | matched | TBI/CTX/TT/ATG | BM + PB | 14 | 0.26 | 2.2 | 0 | 12 | 18 | 100 |
| 5 | 54/M | CML | matched | TBI/CTX/TT/ATG | BM | 23 | ND | — | 0 | 17 | 31 | 100 |
| 6 | 45/M | ALL | mismatched | TBI/CTX/TT/ATG | BM + PB | 11 | 0.54 | 4.9 | 0 | 14 | 28 | 100 |
| 7 | 26/M | RAEB-T | mismatched | TBI/FLU/TT/ATG | BM + PB | 13 | 0.26 | 6.9 | 0 | 11 | 48 | 100 |
| 8 | 45/M | CML | matched | TBI/CTX/TT/ATG | BM | 59 | ND | — | 0 | 52 | 72 | 100 |
| 9 | 50/M | CML | matched | TBI/CTX/TT/ATG | BM | 20 | 0.64 | — | 0 | 10 | 38 | 100 |
| 10 | 36/F | AML | matched | TBI/CTX/TT/ATG | BM + PB | 51 | 1.17 | 2.9 | 0 | 14 | 33 | 100 |
| 11 | 25/M | AML | mismatched | TBI/FLU/TT/ATG | PB | — | — | 7.7 | 0 | 12 | 17 | 100 |
| 12 | 51/M | CML | matched | TBI/CTX/TT/ATG | BM | 45 | ND | — | 0 | 22 | 26 | 100 |
| 13 | 47/M | AML | mismatched | TBI/FLU/TT/ATG | BM + PB | 12 | 0.19 | 4.6 | 0 | 11 | 27 | 100 |
| 14 | 29/F | CML | mismatched | TBI/CTX/TT/ATG | BM + PB | 12 | 0.48 | 9 | 0 | 13 | 16 | 100 |
AML indicates acute myelogenous leukemia; CML, chronic myelogenous leukemia; ALL, acute lymphoblastic leukemia; RAEB-T, refractory anemia with excess of blasts in transformation; TBI, total body irradiation; CTX, cyclophosphamide; TT, thiotepa; ATG, antilymphocyte globulin; FLU, fludarabine; BM, bone marrow; PB, peripheral blood; GVHD, graft-versus-host disease; WBC, white blood cell counts; PLT, platelet counts; ND, not done.